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Cushing's Disease: Dilemmas of Diagnosis and Management 
M. Saeed-uz-Zafar, MD,* Raymond C. Mellinger, MD,* and Max Wisgerhof, MD*
Determining the cause 1Jj" Cus!ting's disease and correcting the ahnormality presents a continuing 
challenge to the clinician despite remar/.:ahle admnces in diagnos1ic and 1herapelllic techniques. 
We present se,·en cases to i/lustraTe I) the classic disorder cured hy pituitary adenomectomy: 2) 
persistence of the disease ajier adenomectomv; 3) Cushi11g·s disease manifesting in the puerperium 
and remilling with dopamine agonist therapv; 4) a p(//ient whose disease relapsed at least ji,·e times 
during 20 years ol treatme/11 hy adre11a/ectomy. pituitary radiation. mitotane. and pilllitary 
adenomectomy: 5) the Nelson syndrome; 6) the ectopic adrenocorticotropic hormone (ACTH) 
syndrome in a patient with dexamethasone suppressihle urinary cortisol who had a pituitary adenoma 
which stained positi,·ely for ACTH hut who was 1101 rnred hy total hypophysecwmy: and 7) a patiem 
whose ACTH-secreting tumor prm·ed fatal despite repeated surgical. radiologic. and pharmaco/ogic 
measures. (Henry Ford Hosp Med J 1991 :39: 10-17) 
Harvey Cushing first described a patient with this disorder in 1912 (I). Twenty years later he reviewed the features of 
similar reported cases, some of whom were found at autopsy to 
have basophilic adenomas of the pituitary. He proposed that this 
pluriglandular disorder resulted from hyperfunction of pituitary 
basophil adenoma (2). Although understanding of the patho­
genesis, diagnosis, and therapy of Cushing's disease advanced 
greatly over the next five decades. dilemmas persist. A condi­
tion similar to Cushing's disease can be produced by nodular or 
neoplastic disease of the adrenal glands as well as by tumors, be­
nign or malignant, arising from either adrenal or pituitary tissue. 
Development of a reliable adrenocorticotropic hormone (ACTH) 
assay provides a ready demonstration when the disorder arises 
from the adrenal glands, for the ACTH levels are very low. 
However, in the presence of normal or elevated ACTH levels. 
the clinician is frequently challenged to identify the source of 
the hormone which is primarily responsible for the syndrome. 
Despite new techniques to measure pituitary and adrenal hor­
mones and advances in radiological methods to study the two 
glands, the ultimate cause may defy detection and not be re­
vealed even at autopsy (3). We present the details of seven pa­
tients with ACTH-dependent Cushing's syndrome to illustrate 
the dilemmas of diagnosis and management encountered in over 
150 similar patients treated at this institution in the last five dec­
ades. 
Classic Cushing's Disease 
Case Report 
Over the space of a few years a 75-year-old retired nurse developed 
facial rounding, centripetal obesity, and multiple ecchymoses. She no­
ticed gradual darkening of her skin, emotional ]ability. somnolence. 
and lethargy, but increasing muscle weakness prompted her to seek 
medical advice. The clinical diagnosis was Cushing's syndrome. Ran-
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dom plasma cortisol was 797 nmol/L (28.9 µg/dL) and the morning fol­
lowing administration of I mg of dexamethasone the level was 830 
nmol/L (30.1 µg/dL). Plasma ACTH concentration was 18 pmol/L (81 
pg/mL) when cortisol was 847 nmol/L (30.7 µg/dL). Twenty-four hour 
urinary cortisol was 549 nmol ( 199 µg). Administration of 8 mg of 
dexamethasone at night resulted in a decline in plasma cortisol to 143 
nmol/L (5.2 µg/dL) and ACTH to less than 2 pmol/L (< 8 pg/mL) the 
next morning. Although the diagnosis of Cushing 's disease seemed es­
tablished, computed tomography (CT) of the sella turcica revealed no 
abnormality. On the strength of the clinical data, transsphenoidal pitu­
itary surgery was recommended and a microadenoma successfully re­
moved. Two days after surgery plasma cortisol was 55 nmol/L (2 µg/ 
dL), and glucocorticoid therapy was required for the subsequent six 
months of gradual clinical improvement. The removed pituitary tissue 
stained heavily with ACTH antibody. 
Comment 
Harvey Cushing noted basophilic pituitary adenomas at au­
topsy in six of eight patients with this disease and proposed that 
these tumors were in some fashion the ultimate cause of the 
hypercortisolism (2). Although the pathogenesis of pituitary 
ACTH hypersecretion is still incompletely understood, there is 
no dispute regarding the central role of the pituitary adenoma. 
The majority of these tumors are small, do not enlarge the sella, 
and may be difficult to detect before surgery by currently avail­
able radiological techniques. Even employing the technique of 
magnetic resonance imaging (MRI), no more than two-thirds of 
the tumors can be demonstrated (4-8). Absence of radiologic ev-
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idence of pituitary tumor in patients who have Cushing's syn­
drome with elevated ACTH levels raises the difficult diagnostic 
dilemma of the ectopic ACTH syndrome. Under these circum­
stances, the 8 mg dexamethasone suppression test originally de­
scribed by Liddle (9) to identify patients with Cushing's disease 
is usually, but not always, completely reliable (I 0). In our expe­
rience with problematic patients, the most promising procedure 
to distinguish Cushing's disease from the ectopic ACTH syn­
drome is the measurement of the ACTH response to cortico­
tropin-releasing hormone (CRH), especially when petrosal si­
nus and peripheral venous samples are compared. Determining 
the serum cortisol response is reported to be additionally infor­
mative ( 11, 12). 
Cushing's Disease Persistent 
After Pituitary Adenomectomy 
Case Report 
A 30-year-old black female first seen in 1981 had a one-year history 
of hypertension, diabetes. amenorrhea. and weight gain. She had no­
ticed multiple ecchymoses, increasing pigmentation over her knuckles, 
and supraclavicular fullness. Blood pressure was 170/100 mm Hg. 
Plasma cortisol was elevated ( 966 nmol/L l35 µg/dL]) but urinary cor­
tisol was only 276 nmol/d ( I 00 µg/24 hrs). Plasma cortisol the morning 
after administration of I mg of dexamethasone was 33 I nmol/L ( 12 µg/ 
dL). The diagnosis of Cushing's disease was thought likely, but the pa­
tient was lost to follow-up for two years. Seen again in 1983 because of 
increasing muscle weakness, her plasma cortisol was high both in the 
morning ( 1.186 nrnol/L [43 µg/dLJ) and afternoon (1,297 nrnol/L l47 
µg/dLJ). Urinary cortisol had risen to 3.863 nmol/d ( 1.400 µg/24 hrs) 
and plasma ACTH was 33 pmol/L ( 152 pg/mL). CT of the sella was re­
ported as normal. After transsphenoidal adenomectomy plasma corti­
sol declined to 152 nmol/L (5.5 µg/dL). The postoperative course was 
complicated by pneumococcal meningitis treated successfully with in­
travenous penicillin. Subsequently, the plasma cortisol value rose to 
497 nmol/L ( 18 µg/dL) and the patient required no exogenous gluco­
corticoids. Because the disease was believed not to have been cured. pi­
tuitary radiation (5,000 rads) was administered and the patient treated 
with mitotane. Early in 1984 she discontinued mitotane of her own vol i­
t ion and eight months later afternoon plasma cortisol level was 433 
nmol/L (15.7 µg/dL). falling to 6 9  nmol/L (2.5 µg/dL) the morning af­
ter I mg of dexamethasone. 
Comment 
The ability to identify intrasellar microadenomas and the de­
velopment of microsurgical techniques revived transsphenoidal 
pituitary surgery. Selective adenomectomy can be performed 
leaving intact the normal pituitary tissue. Even when a pituitary 
adenoma is not identified radiologically, if intrasellar ACTH 
production appears certain, transsphenoidal removal of hyper­
functioning tissue is usually curative (13-17). However, in a 
substantial number of patients, when intrasellar lesions cannot 
be identified and totally removed at surgery, ACTH hypersecre­
tion persists. Such cases require subsequent total hypophysec­
tomy, bilateral adrenalectomy, pituitary irradiation, or pharma­
cologic therapy. In Cushing's disease the hypercortisolism is 
the cause of morbidity and prompt correction is necessary. Al­
though bilateral adrenalectomy usually achieves this end, subse-
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quent regrowth of adrenal remnants or the development of pitu­
itary tumors are possible late complications. 
In the reported patient transsphenoidal surgery was under­
taken despite the absence of radiologic evidence of pituitary 
neoplasm. Although the surgeon identified a pituitary adenoma 
at surgery, its removal did not produce a cure and the patient de­
veloped pneumococcal meningitis. Ultimately, a combination 
of mitotane and pituitary irradiation corrected the hypercorti­
solism. Very possibly, Cushing's disease in this patient could 
have been managed primarily with a combination of mitotane 
and external irradiation. However. reliable criteria are not yet 
available to select such patients. Review of our total experience 
with Cushing's disease suggests that patients whose urinary 17-
hydroxycorticosteroid levels fall more than 50% after admini­
stration of 8 mg of dexamethasone are likely to respond well to 
external irradiation. 
Pituitary irradiation, once frequently used to treat this disor­
der, is not often advised as primary therapy. Conventional ir­
radiation involves administration of 4,400 to 5,000 rads but 
complications increase with doses over 4.800 rads ( 18, 19). Al­
though biochemical and clinical improvement is frequently 
achieved, the reported cure rate from radiation alone is only 
15% to 25% in adults. Significant improvement is said to occur 
in 80% of children treated (20) and when combined with unilat­
eral adrenalectomy radiation therapy achieves a higher remis­
sion rate at all ages (21 ). Conventional radiation requires about 
18 months to attain its maximal effect. With special techniques 
increased intensity of radiation can be delivered to the pituitary 
( 19). Radioactive gold or yttrium-90 implanted surgically by the 
transsphenoidal approach produces a remission rate of 65% and 
an additional 16% of patients are improved (22,23). However, 
the frequency of operative complications is high and panhypo­
pituitarism is commonly the ultimate result. Heavy particle irra­
diation is frequently effective but is not widely available (24). 
Reported side effects include temporary ocular motor distur­
bance, visual loss, hypopituitarism, and secondary neoplasms 
(25-27). Heavy particle therapy requires detailed knowledge of 
the patient's sellar anatomy to guide the beam correctly, and sig­
nificant extrasellar extension is a contraindication to its use (24 ). 
Cushing's Syndrome Developing Postpartum 
Case Report 
A few days after term delivery. this 33-year-old white woman expe­
rienced unexplained rectal hemorrhage. ln the following six weeks she 
experienced emotional !ability, hyperkinesia, weakness, polydipsia, 
and easy bruising. Referred with a diagnosis of fulminant Cushing's 
syndrome possibly due to ectopic ACTH production, she was shown to 
have plasma cortisol as high as 1,545 nmol/L (56 µg/dL) and urinary 
cortisol of 2.83 I nmol/d (1,026 µg/24 hrs) but only minimally elevated 
ACTH of 21 pmol/L ( 97 pg/mL). CT revealed pituitary enlargement. 
After 8 mg of dexamethasone, urinary cortisol rose paradoxically to 
6,896 nmol/d (2,500 µg/24 hrs). Pending etiologic diagnosis, admini­
stration of aminoglutethimide lowered plasma cortisol to 359 nmol/L 
( 13 µg/dL) but was discontinued because of scalp hair loss. Extensive 
investigation failed to disclose any neoplastic disease, and the pituitary 
was shown to be undergoing the expected postpartum involution. At 
this point, therapeutic trial with bromocriptine, 7.5 µg/day. resulted in 
normalization of plasma cortisol and symptomatic improvement. Inter-
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Fig 1-LRvels of ACTH and cortisol during hromocriptine ad­
ministration ro a patient with severe postpartum Cushing' s dis­
ease. The remission has endured for over four years. (From 
McKenna Ml, Linares M, Mellinger RC. Prolonged remission 
of Cushing' s disease following hromocriptine therapy. Henry 
Ford Hosp Med J 1987;35:188-91.) 
ruption of the treatment three months later was followed by laboratory 
and clinical recurrence, so bromocriptine administration was resumed. 
During prolonged treatment, serum cortisol, ACTH, and urine corti ol 
levels usually remained at normal concentrations. The patient was 
symptomatically well except for four transient episodes of weight gain, 
insomnia, and hyperactivity. During one of these episodes urinary cor­
tisol was elevated, but the episodes resolved without adjustment of the 
dose of bromocriptine (Fig I). Treatment was discontinued after 17 
months and the patient has remained in remission for more than four 
years. A detailed case report has been published (28). 
Comment 
Although pituitary hyperfunction is undoubtedly responsible, 
this case raises the question of the pathogenetic mechanism for 
the development of Cushing's disease postpartum and the prob­
able roles played by the anterior and intermediate lobes as well 
as the hypothalamus (29,30). The intermediate lobe, present in 
rudimentary form during intrauterine life, involutes after birth. 
However, these corticotroph cells may proliferate during preg­
nancy. The cells process the ACTH precursor proopiomelano­
cortin somewhat differently from the anterior lobe, have few re­
ceptors for cortisol, but are inhibited by dopamine. Lamberts 
and associates (31) provided evidence for the hypothesis that in 
some patients Cushing's disease results from overactivity of the 
intermediate lobe. Histologic studies with argyrophilic staining 
of removed tissue have been interpreted as revealing neural tis-
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sue in six of 15 adenomas. These six subjects had hyperprolacti­
nemia and responded to a single dose of bromocriptine with a 
decline in prolactin as well as in ACTH levels, but cortisol levels 
were not suppressed by administration of dexamethasone (30, 
31 ). In the management of Cushing 's disease, bromocriptine 
therapy has produced variable results and responses are almost 
always temporary (32,33). Although the disease results from 
primary overactivity of the anterior pituitary, a functional ab­
normality of the hypothalamus may be ultimately responsible in 
some patients. Such cases may not be cured by transsphenoidal 
hypophysectomy. A trial of bromocriptine therapy is recom­
mended in selected patients, particularly those with associated 
hyperprolactinemia, those whose cortisol is not suppressed with 
high-dose dexamethasone, or those whose disease follows preg­
nancy and delivery. 
Multiply Recurrent Cushing's Disease 
Case Report 
This 25-year-old widow was admitted to the hospital in 1969, fol­
lowing a suicide attempt. Her emotional problems were said to have be­
gun following her husband's murder three years earlier. Subsequently. 
she gained weight and developed menstrual irregularities, high blood 
pressure, and changes in body habitus. Laboratory data were consistent 
with a diagnosis ofCushing's disease and in 1968 bilateral adrenalec­
tomy was performed. Thereafter, she received glucocorticoid replace­
ment therapy but was not clinically improved. One year later, after the 
suicide gesture. she was referred to us. On admission, she had florid 
features ofCushing's syndrome and the steroid therapy was withdrawn. 
Plasma cortisol and urinary 17-hydroxycorticoid levels remained well 
above the normal range. The patient was psychotically depressed and 
required psychotropic drug therapy. Pituitary radiation was also admin­
istered in a dose of 5,000 rads. Very little clinical improvement ensued 
and plasma and urinary cortisol levels were well above normal a year 
later. Therapy with mitotane (o,p'-DDD) 2 to 4 g daily was initiated in 
June 1970. 
During the next four years, two remissions, each lasting more than a 
year, were induced by administration of the drug. During the fourth re­
lapse of the disease, the patient experienced a violent headache and 
nausea and vomiting which required hospitalization. Cushing 's disease 
remitted again, pigmentation subsided, and the gonadotropins and thy­
roid-stimulating hormone (TSH) became undetectable (34). 
For the next 10 years the patient was physically and emotionally sta­
ble receiving replacement doses of hydrocortisone, thyroxine, estro­
gen, and progesterone. However, in A pril 1988, the hypercorticism re­
curred yet again although other pituitary functions remained deficient. 
A fter more than a year of variably effective medical management with 
metyrapone, bromocriptine, and trifluoperazine hydrochloride, the pa­
tient agreed to transsphenoidal hypophysectomy. A pituitary adenoma 
was removed, and postoperatively ACTH was undetectable. The clini­
cal remission still endures, but recent ACTH levels have again been 
above the normal range. Chronology of this patient's course is shown in 
the Table. 
Comment 
Before steroid replacement therapy became available, subto­
tal adrenalectomy was the surgical treatment of choice for Cush­
ing's disease, but high rates of either persistent and recurrent hy­
percortisolism or fatal adrenal insufficiency prompted its aban­
donment. Bilateral total adrenalectomy, possible after cortisone 
Cushing·s Disease-Zafar et al 
Table 
Course of Multiply Recurrent Cushing's Disease 
in a 25-Year-Old Woman 
1968: Original diagnosis. Total adrenalectomy. 
I 969: Persistent disease. Pituitary irradiation. 
1970: Persistent disease. Remission after mitotane therapy. 
1972: Relapse. Remission after mitotane therapy. 
1974: Relapse. Remission after mitotane therapy. 
1975: Relapse. Remission after pituitary apoplexy. 
1988: Relapse. Remission after transsphenoidal hypophysectomy. 
1990: ? Relapse. Observation. 
Note: The.most severe symptom, psychotic depression, characterized the disease, but 
abated completely during the remissions. 
became available for clinical use, corrected the hypercortisolism 
but necessitated life-long steroid replacement (35.36). More­
over, progressive hyperpigmentation with the development of a 
pituitary tumor producing ACTH-the Nelson syndrome-was 
reported in about I 0% of such patients (37). Persistent hypercor­
tisolism following total adrenalectomy suggests incomplete re­
moval of the adrenal glands. Persistent high ACTH levels stim­
ulate any remaining adrenal tissue and may be sufficient to pro­
duce a recurrence of the hypercortisolism (38,39). Remnant ad­
renal tissue may represent incomplete surgical removal of hy­
perplastic glands or activation of aberrant adrenal tissue. Acces­
sory and ectopic adrenal cortical tissue has been reported by a 
number of authors (40-42). Localization of functioning adrenal 
remnants may be difficult, the most successful method being ra­
dioactive iodocholesterol scanning ( 43-45). 
This case of multiply recurrent Cushing's disease illustrates 
the difficulties of therapy which characterize some patients. Bi­
lateral adrenalectomy and subsequent pituitary radiation failed 
to produce remission. In our experience either treatment is more 
likely to fail if there has not been significant suppression of 
steroid levels after administration of 8 mg of dexamethasone 
orally. In the reported patient hypercortisolism was repeatedly 
controlled with mitotane but the remissions were not perma­
nent. The disorder was corrected for IO years after pituitary apo­
plexy but ultimately surgical hypophysectomy was required. 
Removal of the pituitary adenoma initially might well have been 
the ideal approach although there is early evidence of still an­
other recurrence. 
The Nelson Syndrome 
Case Report 
A 25-year-old white woman was first treated for Cushing's disease 
in 1953. Adrenal exploration revealed cortical hyperplasia, and she had 
been treated with pituitary radiation, only 2,000 rads. Clinical remis­
sion persisted until 1958 when a suspected relapse was confirmed and 
she received an additional 1,500 rads. Because remission remained in­
complete, bilateral adrenalectomy was performed in 1963. Despite re­
placement glucocorticoid therapy, the patient became progressively 
hyperpigmented and in 1967 had transient left third nerve palsy. She re­
ceived a third course of pituitary irradiation and improved sufficiently 
to continue with only conventional hydrocortisone therapy. By 1978, 
hyperpigmentation was intense and ACTH concentration was I, 718 
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pmol/L (7,800 pg/mL). CT disclosed an intrasellar mass which was re­
moved by the transsphenoidal approach. ACTH level fell to 15 pmol/L 
(67 pg/mL) postoperatively and the pigmentation diminished. In the 
next two years ACTH again rose progressively to over 77 pmol/L 
(> 350 pg/mL) and further pituitary surgery was performed. ACTH 
concentration has remained normal since 1981. 
Comment 
In 1958 Nelson and colleagues (46) described a patient with a 
large pituitary chromophobe adenoma which had developed in 
the three years after bilateral adrenalectomy for Cushing's dis­
ease. The patient had excessive pigmentation, amenorrhea, and 
visual field impairment. ACTH levels which were markedly ele­
vated did not decline normally after intravenous hydrocortisone 
administration. The authors proposed that an ACTH-producing 
tumor had developed in response to the lower cortisol levels 
produced by bilateral adrenalectomy. Incidence of the Nelson 
syndrome, diagnosis of which depends upon the criteria em­
ployed, ranges between 5% to 78% (47-49). Inclusion of those 
patients who have hyperpigmentation but no radiographic evi­
dence of a pituitary tumor increases the incidence. The hyper­
pigmentation and enlarging sellar mass may occur months to 
years after adrenalectomy and ACTH levels may exceed 3,303 
pmol/L (15,000 pg/mL) (37,50). 
Previous pituitary irradiation does not prevent occurrence of 
the Nelson syndrome. contrary to earlier concepts (5 I ,52). Gen­
erally, the syndrome has a benign course characterized by hy­
perpigmentation and slowly progressive changes in the sella tur­
cica. However, some tumors are rapidly progressive, and su­
prasellar extension compresses the optic nerves (53). Some have 
even been considered malignant. Pituitary apoplexy occurs with 
some frequency in these tumors, either spontaneously or in as­
sociation with manipulative procedures (54). 
Development of the Nelson syndrome after bilateral adre­
nalectomy for Cushing's disease cannot be predicted reliably. 
About 90% of the large pituitary tumors demonstrated either 
at the time of diagnosis of Cushing's disease or after adrenal­
ectomy are chromophobe adenomas. An occasional tumor is 
found to be eosinophilic, but more sophisticated techniques 
such as electron microscopy and immunohistochemistry con­
firm that these tumors are composed of corticotroph cells (55). 
Results of treatment of the Nelson syndrome, particularly i_n 
those patients with large invasive tumors, are disappointing. 
Conventional irradiation is effective in only a minority. Heavy 
particle irradiation either with the proton beam or with alpha 
particles is more effective but cannot be used to treat large tu­
mors with extra sellar extension. Surgery, transsphenoidal or 
transfrontal, is usually successful, but recurrences are common. 
Response to administration of cyproheptadine. used in a few 
cases, is variable and unpredictable. Abandonment of total adre­
nalectomy as primary therapy for Cushing's disease in favor of 
transsphenoidal adenomectomy may reduce the frequency of 
the disorder. Patients who have undergone bilateral adrenalec­
tomy should be monitored regularly by means of plasma ACTH 
levels, visual field examinations, and MRI of the pituitary. 
The described patient developed hyperpigmentation several 
years after bilateral adrenalectomy. Prior pituitary irradiation 
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(A) (B) 
Fig 2-Pituitary adenoma removed by transsphenoidal hypophysectomy. A) Hemato.xylin-eosin stain (x 100). B) lmmunoperoxi­
dase stain confirming heavy concentration of ACTH. Removing the adenoma did not lower the plasma ACTH level nor alleviate 
Cushing' s syndrome. After subsequent adrenalectomy, metastatic, ACTH-positive neuroendocrine tumor was demonstrated by liver 
biopsy. 
did not prevent the development of the symptomatic pituitary 
tumor. Transsphenoidal removal of the pituitary tumor, per­
formed twice, did not completely eliminate ACTH secretion and 
mild hyperpigmentation persists. 
Ectopic ACTH Production of Unknown Source 
Case Report 
A 23-year-old white woman was admitted to the hospital for man­
agement of Cushing 's syndrome, symptoms of which had been present 
for two years. Despite the presence of hypokalemia, hyperglycemia, 
and high plasma cortisol (I, 186 nmol/L [ 43 µg/dL]), the urinary corti­
sol level was only slightly above normal (414 nmol/d [ 150 µg/24 hrs]) 
and declined to 22 nmol/d (8 µg/24 hrs) after administration of dexa­
methasone, 2 mg four times a day for two days. Because the patient was 
taking oral contraceptives to regulate her menses, the hypercortisol­
emia was considered to be caused by increased cortisol binding globu­
lin. However, a year later when she was not receiving estrogen, plasma 
cortisol was 828 nmol/L (30 µg/dL) and was not reduced overnight by 
I mg of dexamethasone (910 nmol/L (33 µg/dL]). Moreover. plasma 
ACTH level was 61 pmol/L (276 pg/mL). Cerebral CT was interpreted 
as demonstrating an intrasellar mass while chest x-ray was negative. 
Transsphenoidal hypophysectomy produced no clinical or biochemical 
improvement although the tissue removed stained heavily for ACTH 
and the pathologic diagnosis was ACTH-secreting pituitary adenoma 
(Fig 2). After surgery the ACTH level was 107 pmol/L (485 pg/mL). 
CT of the chest and abdomen revealed no ectopic source for the ACTH 
and reexploration of the sella yielded no additional tumor tissue al­
though the pituitary remnant was removed. The patient became pro­
gressively worse and was confined to bed with muscle weakness. A few 
weeks after the second pituitary operation she developed meningitis 
which responded to antibiotic therapy. Need to correct the progressive 
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Fig 3-Patient after total hypophysectomy and adrenalectomy. 
illness led to bilateral adrenalectomy with gratifying clinical results. 
The patient's strength gradually returned, blood pressure became nor­
mal, and she resumed her usual activity. A few months later, however, 
she developed intense dermal pigmentation (Fig 3), and the ACTH 
level had risen to 2,202 pmol/L ( I 0,000 pg/mL). Repe£1t CT of the ab­
domen now demonstrated a hepatic defect. Tissue obtained by liver bi­
opsy had features of a neuroendocrine tumor and stained intensely for 
ACTH but not for CRF. 
Comment 
The most vexing problem facing the clinician is to differenti­
ate excess ACTH of pituitary origin from one of ectopic source. 
This phenomenon of ectopic ACTH production was one of the 
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first humoral paraneoplastic syndromes described. In 1928, W. 
Hurst Brown (56) reported a patient with oat cell carcinoma of 
the lung who had clinical signs of hypercortisolism and was 
found to have adrenal hyperplasia. Since then increasing num­
bers of patients have been reported to have Cushing's syndrome 
secondary to extra-endocrine benign or malignant tumors. Clin­
ical manifestations vary. Glucose intolerance is frequent and 
frank diabetes may occur. Weakness, hypokalemia, and weight 
loss generally accompany the disorder. However, these features 
are not unique to the ectopic ACTH syndrome and in some pa­
tients the disorder closely mimics Cushing's disease. 
Oat cell carcinoma of the lung is the neoplasm most com­
monly responsible for this disorder. Other reported tumors in­
clude thymoma, carcinoid (thymic, endobronchial, gastric, pan­
creatic), medullary carcinoma of the thyroid, salivary gland tu­
mors, ovarian cancer, islet cell carcinoma of the pancreas, mela­
noma, pheochromocytoma, squamous cell carcinoma of the cer­
vix, and carcinoma of the prostate (57-72). Some of these tu­
mors have been reported to produce CRF in addition to ACTH 
but its biologic significance is not completely understood (73-
76). 
The hypercortisolism of ectopic ACTH syndrome usually 
produces significant morbidity such as hyperglycemia, wasting, 
weakness, and severe electrolyte disturbance. Although treat­
ment which controls hypercortisolism may prolong life, the risk 
of bilateral adrenalectomy is great for these seriously ill pa­
tients, many of whom have malignant tumors. Pharmacologic 
agents which inhibit adrenal secretion provide useful treatment 
(77,78). 
The reported patient demonstrates several problems in diag­
nosis and management. The ectopic production of ACTH was 
not recognized initially, and the location of the primary neo­
plasm continues to evade us. The undoubted presence of a corti­
cotrophic pituitary adenoma is additionally confounding. The 
hypercortisolism was not corrected by removal of this adenoma 
but only by bilateral adrenalectomy. Subsequent generalized 
hyperpigmentation has been severe. 
The Incurable Case 
Case Report 
A 33-year-old white pipe fitter was seen initially in 1975 with signs 
and symptoms of Cushing ·s syndrome. He was mildly hyperpigmented 
and his blood pressure was 170/100 mm Hg. Plasma cortisol level was 
elevated and fell only to 535 nmol/L ( 19.4 µg/dL) the morning after ad­
ministration of I mg of dexamethasone. Urinary 17-hydroxycorticos­
teroids were also high and failed to decline after administration of 8 mg 
of dexamethasone on each of two days ( 151 µmol/d [54.8 mg/24 hrs]). 
ACTH level was 73 pmol/L (333 pg/mL). The diagnosis was Cushing's 
disease, and 5,000 rads of cobalt radiation were administered to the pi­
tuitary area while mitotane ( I to 4 g daily) was taken by mouth. Clinical 
improvement was not sustained and two years later CT revealed a pitu­
itary mass with suprasellar extension. Transsphenoidal hypophysec­
tomy was performed in 1978. Histologic study revealed diffuse fibrosis 
with degenerative changes of the pituitary but no tumor was found. 
Nonetheless. after surgery cortisol therapy was required and ACTH re­
mained at undetectable levels for about three years. In 1983 plasma cor­
tisol concentrations rose again to 1 ,159 nmol/L (42 µg/dL) and mito­
tane therapy was reinstituted. CT of the sell a disclosed a recurrent pitu-
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itary mass. Pituitary tissue removed again by the transsphenoidal ap­
proach revealed only fibrosis although the patient experienced postop­
erative failure of both the gonadotropins and TSH. ACTH remained 
high and the hypercortisolism was controlled with mitotane. Addi­
tional radiation was administered but neither cyproheptadine or bro­
mocriptine administration produced any observable effect. 
By 1987, ACTH levels consistently exceeded 2,202 pmol/L ( I 0,000 
pg/mL), the patient was intensely pigmented, and the pituitary tumor 
had invaded the cavernous sinus and right orbit. A major but subtotal 
excision was accomplished transcranially although the ACTH level re­
mained over 1,321 pmol/L (6,000 pg/mL) and mitotane was required to 
control the adrenal hyperfunction. The pituitary tumor continued to en­
large and the patient died in 1991. 
Comment 
This case demonstrates that currently available methods to 
treat Cushing's disease may be inadequate. This patient under­
went "maximum" pituitary irradiation as well as four attempts at 
surgical removal of the pituitary tumor. He remained uncured. 
Mitotane administration controlled the glucocorticoid excess, 
but huge excesses of ACTH were secreted by the devastating in­
tracranial tumor. 
In this patient urinary 17-hydroxycorticosteroids were not 
suppressed by administration of 8 mg of dexamethasone before 
he had received any therapeutic intervention. ln our experience 
such data suggest a poor prognosis and aggressive surgical treat­
ment should be undertaken at the outset. 
Summary 
Harvey Cushing's great contribution at the beginning of this 
century was to establish the role of pituitary adenoma in the gen­
esis of the disease that bears his name. Although the pituitary 
adenoma is now clearly understood to be the cause of the classic 
disorder, variable results of medical, radiologic, and surgical 
treatment as well as the propensity to recurrence and invasion 
make management a serious dilemma. Moreover, a clinically 
similar disorder can be produced not only by hyperfunctioning 
adrenal neoplasms but also by ACTH produced ectopically in a 
variety of "nonendocrine" tumors. The true source of ACTH 
hypersecretion, the incompletely understood involvement of the 
hypothalamus, and the possible return of pituitary hyperfunc­
tion after surgery are considerations which can confound the di­
agnostician. Despite spectacular radiologic advances, imaging 
studies can be misleading. We believe that of the currently avail­
able diagnostic techniques, the measurement of ACTH gradient 
in the petrosal sinuses and peripheral vein blood obtained simul­
taneously after CRH administration is the most reliable means 
of identifying the source of ACTH excess. 
The success of therapy, which at best is unpredictable, de­
pends first of all on accurate diagnosis of the disease. When 
Cushing's disease is due to a pituitary adenoma, transsphe­
noidal adenomectomy is often ideal treatment. 
Recurrence of the disease after pituitary adenomectomy may 
respond to irradiation. Despite a disappointing rate of remission, 
radiotherapy should not be dismissed as primary therapy, espe­
cially in conjunction with medical measures to control adrenal 
hyperfunction. Neither should medical control of the pituitary 
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gland be overlooked, especially in atypical cases such as the re­
ported patient with puerperal onset of the disorder. Ectopically 
secreted ACTH can mimic pituitary hyperfunction precisely or 
coexist with it. In such cases, accurate preoperative diagnosis 
may not be possible at the present time, and the ultimate source 
of the disorder will continue to defy demonstration. Finally, 
given the ability of the pituitary adenoma to recur and invade, 
resisting all present measures to control the disease, some pa­
tients with Cushing's disease will remain uncured and incur­
able. 
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